The impact of sick sinus syndrome on flow velocity of the left atrial appendage in patients with atrial fibrillation

Back

ESC Professional Premium Access

The impact of sick sinus syndrome on flow velocity of the left atrial appendage in patients with atrial fibrillation

Session: The role of rate control and comorbidities in atrial fibrillation

Topic: Detection of Underlying Heart Disease

Speaker: Doctor S. Takahashi (Kobe, JP)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Satoshi Takahashi

Kawasaki Hospital, Kobe (Japan)

0 follower

5 more presentations in this session

Interactions of circulating, digoxin-like, steroids with rate control therapy for atrial fibrillation in the RATE-AF randomised clinical trial

Speaker: Doctor I. Akoumianakis (Birmingham, GB)

Ranolazine is associated with a reduced incidence of atrial fibrillation in patients with chronic coronary syndrome: the results of a real-world analysis of an Italian population

Speaker: Associate Professor S. Fumagalli (Florence, IT)

High levels of intermediate cd14++cd16+ monocytes predict incident atrial fibrillation in the general population

Speaker: Doctor K. Sveen (Oslo, NO)

Clinical impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study

Speaker: Professor L. Fauchier (Tours, FR)

Is pre-diabetes a predictor of events in patients with atrial fibrillation?

Speaker: Doctor A. Ledo Pineiro (Vigo, ES)

Access the full session

The role of rate control and comorbidities in atrial fibrillation

Speakers: Doctor S. Takahashi, Doctor I. Akoumianakis, Associate Professor S. Fumagalli, Doctor K. Sveen, Professor L. Fauchier...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

The impact of sick sinus syndrome on flow velocity of the left atrial appendage in patients with atrial fibrillation

About the speaker

Doctor Satoshi Takahashi

5 more presentations in this session

Interactions of circulating, digoxin-like, steroids with rate control therapy for atrial fibrillation in the RATE-AF randomised clinical trial

Ranolazine is associated with a reduced incidence of atrial fibrillation in patients with chronic coronary syndrome: the results of a real-world analysis of an Italian population

High levels of intermediate cd14++cd16+ monocytes predict incident atrial fibrillation in the general population

Clinical impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study

Is pre-diabetes a predictor of events in patients with atrial fibrillation?

Access the full session

The role of rate control and comorbidities in atrial fibrillation

About the event

ESC Congress 2023

ESC 365 is supported by